According to the depth of tumor invasion, bladder cancer is divided into non-muscular invasive bladder cancer and muscular invasive bladder cancer. As a highly heterogeneous disease, Bladder cancer varies greatly in its histological type, prognosis and response to treatment. Traditional histopathological subtypings can no longer meet the needs of patients’ clinical diagnosis and treatment, so there is an urgent need to find molecular subtypings that can mark tumor biological behavior and provide guidance for clinical treatment. With the development of gene expression profile, studies on molecular subtypings of bladder cancer based on molecular expression differences provide an important theoretical basis for solving the heterogeneity of bladder cancer, judging the prognosis and guiding the individualized treatment of patients.